ROVI leads the BioElast Consortium approved in the 2021 Call for Projects in Public-Private Collaboration of the MCIN (AEI)

The project led by Laboratorios Farmacéuticos ROVI, "Bioreactors and Biotints with heparin for the regeneration of Elastic Tissues (BioElasT)", obtains funding.

Madrid: 28 of December 2022

The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (BioElasT)”, led by Laboratorios Farmacéuticos ROVI, S.A., in collaboration with the company Regemat 3D, S.L. and the Basque Centre for Macromolecular Design and EngineeringPolymatFundazioa, University of the Basque Country Euskal Herriko Unibertsitatea and Consorcio Centro de Investigación Biomédica in Red M.P. (CIBER, has been funded by MCIN/AEI/10.13039/ 501100011033 and by the European Union-NextGenerationEU/PRTR, through the call for the 2021 Public-Private Collaboration program (CPP2021-008754).

The objective of the call for grants to public-private partnership projects is to support experimental development in cooperation between companies and research organizations, promoting the development of new technologies, the business application of new ideas and techniques; and contributing to the creation of new products and services. With this, it also seeks to facilitate the transfer of knowledge through actions that eliminate the existing barriers between the different actors in the public and private spheres and increase the dissemination and communication capacities of R+D+i to society by contributing to the fulfilment of specific objective 5 (SO5) of the State Plan for Scientific, Technical and Innovation Research for the period 2021-2023.

No votes yet
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug...
4 min
Madrid, 12 March 2024 Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, ROVI), informs of the agreement that has been concluded with...
3 min
ROVI ACHIEVED OPERATING REVENUE GROWTH OF 1% IN THE FIRST POST-PANDEMIC YEAR Operating revenue increased 1% to 829.5 million euros in...
4 min